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 ABSTRACT
Brain natriuretic peptides are elevated in 
circulation in proportion to a decrease in 
myocardial function. They have been uni-
formly shown to have excellent negative 
predictive value in differential diagnosis of 
dyspnoea. They can also be used in diag-
nosing heart failure and have been recently 
shown as possible prognostic markers in 
acute coronary syndrome and pulmonary 
embolism. It is important to note that 
brain natriuretic peptide values rise with 
age and are inversely proportional to body 
mass index and glomerular filtration rate.
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Heart failure (HF) affects 1-3% of the gen-
eral population and approximately 10% of 
the elderly. Healthcare spending for chron-
ic HF accounts for 1-2% of total healthcare 
expenditure in developed countries. Im-
proved survival following acute myocar-
dial infarction (AMI) and resultant struc-
tural cardiac abnormalities have led to an 
increased incidence of clinical HF. Chronic 
HF patients have frequent short-term re-
admission rates, meaning that about 30% 
of HF patients are readmitted within 30 
days. 
Brain natriuretic peptide was first de-
scribed after being isolated from porcine 
brain tissue in 1988 and thus obtained its 
name. Soon afterwards it was established 
that the main biosynthesis of this peptide 
takes place in the cardiomyocytes within 
the ventricles and it steadily increases 
in proportion to a decrease in myocar-
dial function. The precursor molecule is 
pre-proBNP which is then cleaved into 
proBNP, a peptide consisting of 108 ami-
noacids. The longer the peptide molecule, 
the better is its stability both in vivo and in 
vitro. This is why proBNP is substantially 
more stable in serum after blood with-
drawal than BNP, which is a final biologi-
cally active molecule consisting of only 32 
aminoacids. NT-proBNP is actually a bio-
logically inactive peptide which originates 
as a consequence of proteolytic cleavage 
of proBNP by an enzyme called corin, but 
since it is 76 aminoacids long, it has a sub-
stantial advantage of sufficient in vitro sta-
bility as compared to BNP.
The main stimulus for increased BNP and 
NT-proBNP synthesis and release into the 
circulation is myocardial wall stress. Bio-
chemically, its mode of action is analogous 
to all other peptide hormones, which is 
to stimulate relevant membrane receptors 
on target cells. BNP stimulates natriuretic 
peptide receptor type A that stimulates 
intracellular cyclic guanosine monophos-
phate production. This production in turn 
triggers further biochemical cascades re-
sulting in natriuresis and diuresis, periph-
eral vasodilatation and inhibition of renin-
angiotensin and aldosterone system, which 
all serve to counterbalance the negative ef-
fects of deteriorating myocardial function.
Being a small molecule, the in vivo half 
life of BNP is only 20 minutes, as com-
pared to half life of NT-proBNP which is 
about 120 minutes, a fact explaining much 
higher normal serum values of the latter 
although both molecules arise in equimo-
lar proportions. Also, the bigger size of the 
NT-proBNP eliminates the possibility for 
most of the pre-analytical mistakes, which 
may be a potential cause for erroneously 
low results due to degradation process in 
vitro. When converted to absolute patient 
numbers, the use of BNP rather than NT-
proBNP in an acute care setting potentially 
increased the false negative test results by 
between 0.8 and 3.1%.
Since NT-proBNP is primarily excreted 
through kidneys, its value rises in parallel 
with deteriorating renal function, so this 
must be taken into account when evaluat-
ing the results in renal patients (figure 1) 
 
Figure 1. The relation of brain natriuretic 
peptide and glomerular filtration rate
BNP - brain natriuretic peptide
CHF - congestive heart failure
eGFR - estimated glomerular filtration rate
Both NT-proBNP and BNP serum con-
centrations normally rise with age, which 
is why the use of age-related cut-off values 
has been recommended by some studies. 
However, even though the levels of natriu-
retic peptides do increase with age, this 
may have consequences on the test speci-
ficity, but it does not affect its sensitivity, 
i.e. its excellent ability to serve as a heart 
failure rule-out test. 
Both BNP and NT-proBNP have high 
week-to-week intra-individual coefficients 
of variation of 113% and 98%, respectively, 
with the biological variation being consist-
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ently higher for BNP probably due to its 
shorter half life in circulation.
It is also very important to take into ac-
count the patient’s BMI because the values 
in obese patients have consistently been 
shown to be significantly lower than in 
normal weight patients. In other words, 
they are inversely proportional to BMI 
(figure 2), so there is a danger of misclas-
sifying obese patients on the basis of their 
natriuretic peptide value.
Figure 2. NT-proBNP and BNP value dis-
tribution according to BMI
BMI - body mass index
BNP - brain natriuretic peptide
NT-proBNP - N-terminal pro brain natriu-
retic peptide
DIAGNOSTIC SIGNIFICANCE
In the following clinical situations, the 
above mentioned effects of deteriorated re-
nal function, obesity and/or advancing age 
must be taken into account.
1. Acute dyspnoea – differential diag-
nosis
The most common causes of unclear dysp-
noea in the emergency department are 
congestive heart failure (CHD), chronic 
obstructive pulmonary disease (COPD), 
acute coronary syndrome (ACS), asthma, 
pneumonia and pulmonary embolism. It 
has been clearly established that natriu-
retic peptides demonstrate excellent sen-
sitivities, i.e. negative predictive values in 
excluding myocardial causes of dyspnoea. 
The newest systematic reviews point out 
that negative likelihood ratios for both 
BNP and NT-proBNP are around 0.12. Of 
course, if the clinical scenario is fairly clear 
and strongly suggestive of heart failure or, 
conversely, points to an alternative diagno-
sis, there is no need to perform the assay. 
It also has to be taken into account that 
newer studies point to the fact that natriu-
retic peptides are often markedly elevated 
in cases of pulmonary embolism, so a posi-
tive value is not heart-specific.
2. Diagnosing heart failure
The diagnosis of heart failure (HF) is often 
challenging, as the symptoms and signs 
may be non-specific and may occur in 
other non-cardiac diseases. The mortality 
from HF remains high, at approximately 
25% over one year, which could be reduced 
through prompt diagnosis and treatment. 
The 2012 European Society of Cardiol-
ogy guidelines for heart failure include 
specific age-independent decision limits 
for natriuretic peptides for the exclusion 
of acute heart failure (NT-proBNP ≤ 300 
ng/L, BNP ≤ 100 ng/L). Conversely, HF 
inclusion criteria for NT-proBNP are age-
dependent, as shown in table 1.
Although natriuretic peptide levels have 
been used widely for the early diagnosis 
or exclusion of chronic heart failure in the 
outpatient setting, their use in the acute 
care setting has only partially been adopt-
ed. However, these tests have excellent 
ability to exclude the diagnosis of acute 
heart failure, with sensitivities approach-
ing 1 and will therefore hardly misclassify 
any cases of possible acute heart failure 
when used as a rule-out test. A negative 
test result will reduce or eliminate the need 
to proceed to echocardiography or other 
imaging methods, allowing a more effi-
cient use of resources. On the other hand, 
the specificity is relatively low (about 60%, 
although it increases with increasing nu-
merical value), thus confirmatory testing 
by cardiac imaging is required. It is there-
fore of utter importance for natriuretic 
peptide values which fall above the rule-
out thresholds to correlate the information 
with other diagnostic and clinical data in 
order to exclude non-cardiac causes of el-
evated results, such as pulmonary embo-
lism, sepsis or renal failure. 
3. Emerging data: risk stratification – 
acute coronary syndrome and pulmo-
nary embolism
The spectrum of acute coronary syn-
drome (ACS), from ST segment elevation 
myocardial infarction to unstable angina 
without irreversible myocardial necrosis, 
induces increased plasma concentrations 
of natriuretic peptides. Activation of the 
BNP gene is caused by acute ischemia 
with tissue hypoxia as well as by increased 
myocardial stretch secondary to ischemia-
induced left ventricular systolic and/or di-
astolic dysfunction. Multiple biomarkers 
at admission significantly improve the pre-
diction of mortality in patients undergoing 
primary percutaneous coronary interven-
tion for acute ST-segment elevation myo-
cardial infarction and it has been shown 
that NT-proBNP above 600 ng/L doubles 
the mortality risk.
Several studies performed in patients with 
acute pulmonary embolism have dem-
onstrated that NT-proBNP value was as-
sociated with the likelihood for death or 
escalation of therapy with an odds ratio of 
nearly 15, and a negative predictive value 
of 97%. Essentially, the lower the values of 
NT-proBNP are, the lower is the likelihood 
for complications.
CONCLUSION
Both BNP and NT-proBNP have been 
shown to represent added value in differ-
ential diagnosis of dyspnoea, as well as in 
diagnosing and monitoring heart failure. 
Recent studies also point at their possible 
prognostic significance in acute coronary 
syndrome and pulmonary embolism. 
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Table 1, NT-proBNP values in heart failure 
Heart failure unlikely Grey zone Heart failure likely
- send patient to imaging - confirm by imaging
≤ 300 In between 300 and age-related 
inclusion cut-off
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